Lilly

Lilly 2Q10

2Q10 Revenues: $5.7 billion (+9%)

2Q10 Earnings: $1.3 billion (+16%)

YTD Revenues: $11.2 billion (+9%)

YTD Earnings: $2.7 billion (+5%)

Comments: Zyprexa revenues were up 5% in 2Q10 and 7% in YTD to $1.3 billion and $2.5 billion, respectively. U.S. sales of the drug were up 10% in 2Q10 to $638 million. Cymbalta revenues were up 17% ($868 million) and 15% ($1.7 billion) during those spans, while Alimta rose 43% ($552 million) and 50% ($1.1 billion) for 2Q10 and YTD. Effient sales were $22.9 million in 2Q10, following an $8.8 million performance in 1Q10. R&D expenses were up 14% in 2Q10 to $1.2 billion and 12% YTD to $2.2 billion. The increase was due to late-stage products and milestone payments.